These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
205 related articles for article (PubMed ID: 34973508)
1. Tuberculosis drug discovery: Progression and future interventions in the wake of emerging resistance. Perveen S; Kumari D; Singh K; Sharma R Eur J Med Chem; 2022 Feb; 229():114066. PubMed ID: 34973508 [TBL] [Abstract][Full Text] [Related]
2. Pang Y; Zong Z; Huo F; Jing W; Ma Y; Dong L; Li Y; Zhao L; Fu Y; Huang H Antimicrob Agents Chemother; 2017 Oct; 61(10):. PubMed ID: 28739779 [TBL] [Abstract][Full Text] [Related]
3. In vitro interaction profiles of the new antitubercular drugs bedaquiline and delamanid with moxifloxacin against clinical Mycobacterium tuberculosis isolates. Chandramohan Y; Padmanaban V; Bethunaickan R; Tripathy S; Swaminathan S; Ranganathan UD J Glob Antimicrob Resist; 2019 Dec; 19():348-353. PubMed ID: 31226332 [TBL] [Abstract][Full Text] [Related]
4. Delamanid, Bedaquiline, and Linezolid Minimum Inhibitory Concentration Distributions and Resistance-related Gene Mutations in Multidrug-resistant and Extensively Drug-resistant Tuberculosis in Korea. Yang JS; Kim KJ; Choi H; Lee SH Ann Lab Med; 2018 Nov; 38(6):563-568. PubMed ID: 30027700 [TBL] [Abstract][Full Text] [Related]
5. Emergence of Low-level Delamanid and Bedaquiline Resistance During Extremely Drug-resistant Tuberculosis Treatment. Polsfuss S; Hofmann-Thiel S; Merker M; Krieger D; Niemann S; Rüssmann H; Schönfeld N; Hoffmann H; Kranzer K Clin Infect Dis; 2019 Sep; 69(7):1229-1231. PubMed ID: 30933266 [TBL] [Abstract][Full Text] [Related]
6. Optimized Background Regimen for Treatment of Active Tuberculosis with the Next-Generation Benzothiazinone Macozinone (PBTZ169). Lupien A; Vocat A; Foo CS; Blattes E; Gillon JY; Makarov V; Cole ST Antimicrob Agents Chemother; 2018 Nov; 62(11):. PubMed ID: 30126954 [TBL] [Abstract][Full Text] [Related]
7. Filling the pipeline - new drugs for an old disease. Stehr M; Elamin AA; Singh M Curr Top Med Chem; 2014; 14(1):110-29. PubMed ID: 24236723 [TBL] [Abstract][Full Text] [Related]
8. Bedaquiline and delamanid for drug-resistant tuberculosis: a clinician's perspective. Guglielmetti L; Chiesi S; Eimer J; Dominguez J; Masini T; Varaine F; Veziris N; Ader F; Robert J Future Microbiol; 2020 Jun; 15():779-799. PubMed ID: 32700565 [TBL] [Abstract][Full Text] [Related]
9. Pulmonary resection combined with isoniazid- and rifampin-based drug therapy for patients with multidrug-resistant and extensively drug-resistant tuberculosis. Park SK; Kim JH; Kang H; Cho JS; Smego RA Int J Infect Dis; 2009 Mar; 13(2):170-5. PubMed ID: 18768342 [TBL] [Abstract][Full Text] [Related]
10. Recent controversies about MDR and XDR-TB: Global implementation of the WHO shorter MDR-TB regimen and bedaquiline for all with MDR-TB? Dheda K; Cox H; Esmail A; Wasserman S; Chang KC; Lange C Respirology; 2018 Jan; 23(1):36-45. PubMed ID: 28850767 [TBL] [Abstract][Full Text] [Related]
11. Trends in the discovery of new drugs for Mycobacterium tuberculosis therapy with a glance at resistance. Lohrasbi V; Talebi M; Bialvaei AZ; Fattorini L; Drancourt M; Heidary M; Darban-Sarokhalil D Tuberculosis (Edinb); 2018 Mar; 109():17-27. PubMed ID: 29559117 [TBL] [Abstract][Full Text] [Related]
12. Applicability of the shorter 'Bangladesh regimen' in high multidrug-resistant tuberculosis settings. Sotgiu G; Tiberi S; Centis R; D'Ambrosio L; Fuentes Z; Zumla A; Migliori GB Int J Infect Dis; 2017 Mar; 56():190-193. PubMed ID: 27816662 [TBL] [Abstract][Full Text] [Related]
14. Delamanid and Bedaquiline Resistance in Mycobacterium tuberculosis Ancestral Beijing Genotype Causing Extensively Drug-Resistant Tuberculosis in a Tibetan Refugee. Hoffmann H; Kohl TA; Hofmann-Thiel S; Merker M; Beckert P; Jaton K; Nedialkova L; Sahalchyk E; Rothe T; Keller PM; Niemann S Am J Respir Crit Care Med; 2016 Feb; 193(3):337-40. PubMed ID: 26829425 [No Abstract] [Full Text] [Related]
15. Evolution of Extensively Drug-Resistant Tuberculosis over Four Decades: Whole Genome Sequencing and Dating Analysis of Mycobacterium tuberculosis Isolates from KwaZulu-Natal. Cohen KA; Abeel T; Manson McGuire A; Desjardins CA; Munsamy V; Shea TP; Walker BJ; Bantubani N; Almeida DV; Alvarado L; Chapman SB; Mvelase NR; Duffy EY; Fitzgerald MG; Govender P; Gujja S; Hamilton S; Howarth C; Larimer JD; Maharaj K; Pearson MD; Priest ME; Zeng Q; Padayatchi N; Grosset J; Young SK; Wortman J; Mlisana KP; O'Donnell MR; Birren BW; Bishai WR; Pym AS; Earl AM PLoS Med; 2015 Sep; 12(9):e1001880. PubMed ID: 26418737 [TBL] [Abstract][Full Text] [Related]
16. Tuberculosis: An Update on Pathophysiology, Molecular Mechanisms of Drug Resistance, Newer Anti-TB Drugs, Treatment Regimens and Host- Directed Therapies. Borah P; Deb PK; Venugopala KN; Al-Shar'i NA; Singh V; Deka S; Srivastava A; Tiwari V; Mailavaram RP Curr Top Med Chem; 2021; 21(6):547-570. PubMed ID: 33319660 [TBL] [Abstract][Full Text] [Related]
17. Tuberculosis Drug Development: History and Evolution of the Mechanism-Based Paradigm. Chakraborty S; Rhee KY Cold Spring Harb Perspect Med; 2015 Apr; 5(8):a021147. PubMed ID: 25877396 [TBL] [Abstract][Full Text] [Related]
18. Plan to combat extensively drug-resistant tuberculosis: recommendations of the Federal Tuberculosis Task Force. Centers for Disease Control and Prevention (CDC) MMWR Recomm Rep; 2009 Feb; 58(RR-3):1-43. PubMed ID: 19214162 [TBL] [Abstract][Full Text] [Related]
19. Classical against molecular-genetic methods for susceptibility testing of antituberculotics. Porvaznik I; Mokry J; Solovic I Adv Exp Med Biol; 2015; 835():15-22. PubMed ID: 25252893 [TBL] [Abstract][Full Text] [Related]
20. Advances in the treatment of tuberculosis. Zhang Y Clin Pharmacol Ther; 2007 Nov; 82(5):595-600. PubMed ID: 17898708 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]